Chugai’s RG6042 Receives MHLW’s Orphan Drug Designation for Huntington’s Disease in Japan

 Chugai’s RG6042 Receives MHLW’s Orphan Drug Designation for Huntington’s Disease in Japan

Chugai’s RG6042 Receives MHLW’s Orphan Drug Designation for Huntington’s Disease in Japan

Shots:

  • The MHLW has granted Chugai’s RG6042 an ODD for the expected treatment of Huntington’s disease
  • The RG6042 is currently being evaluated in P-III GENERATION HD1 study and is expected to delay the progression of Huntington’s disease as the first disease-modifying therapy
  • RG6042 (ONIS-HTTRx) is an antisense oligonucleotide targeting HTT mRNA and has received FDA & EMA’s ODD for the Huntington’s disease in May & Dec’2015 with EMA’s PRIME designation in 2018

Click here ­to­ read full press release/ article | Ref: Chugai | Image: Wikipedia

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post